Evidence map›Paper›PMID 30189015›Full record

ArticleMutagenesis2019

Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: is aromatic N-oxide a structural alert for predicting DNA-reactive mutagenicity?

Alexander Amberg, Lennart T Anger, Joel Bercu, David Bower, Kevin P Cross, Laura Custer, James S Harvey, Catrin Hasselgren, Masamitsu Honma, Candice Johnson and 13 more

Abstract read
In one paragraph

Article in Mutagenesis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Structure-mutagenicity relationships on quinoline and indole analogues in the Ames test.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2024
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Alexander AmbergSanofi, R&D Preclinical Safety Frankfurt, Industriepark Höchst, Frankfurt am Main, Germany.
Lennart T AngerSanofi, R&D Preclinical Safety Frankfurt, Industriepark Höchst, Frankfurt am Main, Germany.
Joel BercuGilead Sciences, Nonclinical Safety and Pathobiology, Foster City, CA, USA.
David BowerLeadscope, Inc., Columbus, OH, USA.
Kevin P CrossLeadscope, Inc., Columbus, OH, USA.
Laura CusterBristol-Myers Squibb, Drug Safety Evaluation, New Brunswick, NJ, USA.
James S HarveyGlaxoSmithKline Pre-Clinical Development, Ware, Hertfordshire, UK.
Catrin HasselgrenGenentech, Inc., Safety Assessment, South San Francisco, CA, USA.
Masamitsu HonmaNational Institute of Health Sciences, Division of Genetics & Mutagenesis, Kamiyoga, Setagaya-ku, Tokyo, Japan.
Candice JohnsonLeadscope, Inc., Columbus, OH, USA.
Robert JollyToxicology Division, Eli Lilly and Company, Indianapolis, IN, USA.
Michelle O KenyonPfizer Worldwide Research and Development, Drug Safety, Genetic Toxicology, Groton, CT, USA.
Naomi L KruhlakU.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA.
Penny LeavittBristol-Myers Squibb, Drug Safety Evaluation, New Brunswick, NJ, USA.
Donald P QuigleyLeadscope, Inc., Columbus, OH, USA.
Scott MillerLeadscope, Inc., Columbus, OH, USA.
David SnodinXiphora Biopharma Consulting, Bristol, UK.
Lidiya StavitskayaU.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA.
Andrew TeasdaleAstraZeneca, Pharmaceutical Technology and Development, Macclesfield, Cheshire, UK.
Alejandra Trejo-MartinAstraZeneca, Pharmaceutical Technology and Development, Macclesfield, Cheshire, UK.
Angela T WhiteGlaxoSmithKline Pre-Clinical Development, Ware, Hertfordshire, UK.
Joerg WichardBayer AG, Pharmaceuticals Division, Investigational Toxicology, Muellerstr, Berlin, Germany.
Glenn J MyattLeadscope, Inc., Columbus, OH, USA.

Funding

Rapid response toxicology prediction platformR44ES026909 · NIEHS · LEADSCOPE, INC. · PI MYATT, GLENN JOHN · 2018 to 2019
$1000k
NIEHS NIH HHS R44 ES026909
6 · The paper itself

Abstract

(Quantitative) structure-activity relationship or (Q)SAR predictions of DNA-reactive mutagenicity are important to support both the design of new chemicals and the assessment of impurities, degradants, metabolites, extractables and leachables, as well as existing chemicals. Aromatic N-oxides represent a class of compounds that are often considered alerting for mutagenicity yet the scientific rationale of this structural alert is not clear and has been questioned. Because aromatic N-oxide-containing compounds may be encountered as impurities, degradants and metabolites, it is important to accurately predict mutagenicity of this chemical class. This article analysed a series of publicly available aromatic N-oxide data in search of supporting information. The article also used a previously developed structure-activity relationship (SAR) fingerprint methodology where a series of aromatic N-oxide substructures was generated and matched against public and proprietary databases, including pharmaceutical data. An assessment of the number of mutagenic and non-mutagenic compounds matching each substructure across all sources was used to understand whether the general class or any specific subclasses appear to lead to mutagenicity. This analysis resulted in a downgrade of the general aromatic N-oxide alert. However, it was determined there were enough public and proprietary data to assign the quindioxin and related chemicals as well as benzo[c][1,2,5]oxadiazole 1-oxide subclasses as alerts. The overall results of this analysis were incorporated into Leadscope's expert-rule-based model to enhance its predictive accuracy.

Indexed as

Quantitative Structure-Activity RelationshipCyclic N-OxidesDNA DamageMutagenesisMutagenicity TestsMutagensCyclic N-OxidesMutagens

Identifiers

PMID30189015
PMCPMC6402318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.